German pharmaceutical company BioNTech was back in profit in the third quarter of 2024, it announced on Monday, with comparatively early approvals for adapted coronavirus vaccines driving up sales. Overall, revenues amounted to €1.24 billion ($1.34 billion) at the Mainz-based company, which became famous early in the coronavirus pandemic in 2020 for quickly developing a vaccine. The firm made a profit of €198.1 million, compared with a loss of almost €808 million in the previous quarter. The variant-adapted Covid-19 vaccines were brought to market earlier than in the previous year due to regul…